GSK plc reported 13 holdings worth US$602M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 13, 2026
GSK plc reported 13 holdings worth US$602M as of Jun 30, 2026. Largest: Vir Biotechnology, Inc., Ideaya Biosciences, Inc. and Cytokinetics, Incorporated. Filed Aug 13, 2026 (Form 13F).
- Holdings
- 13
- Value as reported
- US$602M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Vir Biotechnology, Inc. | 8.55M | US$87.1M | 14.5% |
| Ideaya Biosciences, Inc. | 1.33M | US$49.7M | 8.3% |
| Cytokinetics, Incorporated | 340K | US$29M | 4.8% |
| Lyell Immunopharma, Inc. | 1.51M | US$21.3M | 3.5% |
| Spero Therapeutics, Inc. | 9.19M | US$20.3M | 3.4% |
| Nkarta, Inc. | 3.15M | US$8.92M | 1.5% |
| Fulcrum Therapeutics, Inc. | 1.79M | US$6.54M | 1.1% |
| Cvrx, Inc. | 1.01M | US$5.18M | 0.86% |
| Regenxbio Inc. | 271K | US$3.25M | 0.54% |